1
|
NEZİR AE, BOLAT ZB, SAKA OM, ZEMHERİ IE, GÜLYÜZ S, ÖZKÖSE UU, YILMAZ Ö, BOZKIR A, ŞAHİN F, TELCİ D. PEtOx-DOPE nanoliposomes functionalized with peptide 563 in targeted BikDDA delivery to prostate cancer. Turk J Biol 2024; 48:174-181. [PMID: 39050711 PMCID: PMC11265899 DOI: 10.55730/1300-0152.2693] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2024] [Revised: 06/26/2024] [Accepted: 05/23/2024] [Indexed: 07/27/2024] Open
Abstract
Background Nanocarrier-based systems have cultivated significant improvements in prostate cancer therapy. However, the efforts are still limited in clinical applicability, and more research is required for the development of effective strategies. Here, we describe a novel nanoliposomal system for targeted apoptotic gene delivery to prostate cancer. Methods Poly (2-ethyl-2-oxazoline) (PEtOx) dioleoyl phosphatidylethanolamine (DOPE) nanoliposomes were conjugated with the prostate-specific membrane antigen (PSMA)-targeting peptide GRFLTGGTGRLLRIS (P563) and loaded with BikDDA, a mutant form of the proapoptotic Bik. We selected 22Rv1 cells with moderate upregulation of PSMA to test the in vitro uptake, cell death, and in vivo anticancer activity of our formulation, P563-PEtOx-DOPE-BikDDA. Results BikDDA was upregulated in 22Rv1 cells, inducing cell death, and CD-1 nude mice xenografts administered with the formulation showed significant tumor regression. Conclusion We suggest that P563-PEtOx-DOPE-BikDDA nanoliposomes can serve as prominent gene carriers against prostate cancer.
Collapse
Affiliation(s)
- Ayca Ece NEZİR
- Department of Genetics and Bioengineering, Faculty of Engineering, Yeditepe University, İstanbul,
Turkiye
| | - Zeynep Büşra BOLAT
- Department of Genetics and Bioengineering, Faculty of Engineering, Yeditepe University, İstanbul,
Turkiye
- Department of Molecular Biology and Genetics, Hamidiye Institute of Health Sciences, University of Health Sciences, İstanbul,
Turkiye
- Experimental Medicine Research and Application Center, University of Health Sciences, İstanbul,
Turkiye
| | - Ongun Mehmet SAKA
- Department of Pharmaceutical Technology, Faculty of Pharmacy, Ankara University, Ankara,
Turkiye
| | - Itır Ebru ZEMHERİ
- Department of Pathology, Ümraniye Training and Research Hospital, University of Health Sciences, İstanbul,
Turkiye
| | - Sevgi GÜLYÜZ
- Materials Technologies, Marmara Research Center, TÜBİTAK, Kocaeli,
Turkiye
- Department of Chemistry, Faculty of Science and Letters, İstanbul Technical University, İstanbul,
Turkiye
| | - Umut Uğur ÖZKÖSE
- Materials Technologies, Marmara Research Center, TÜBİTAK, Kocaeli,
Turkiye
- Department of Chemistry, Faculty of Science and Letters, İstanbul Technical University, İstanbul,
Turkiye
- Department of Chemistry, Faculty of Science and Letters, Piri Reis University, İstanbul,
Turkiye
| | - Özgür YILMAZ
- Materials Technologies, Marmara Research Center, TÜBİTAK, Kocaeli,
Turkiye
| | - Asuman BOZKIR
- Department of Pharmaceutical Technology, Faculty of Pharmacy, Ankara University, Ankara,
Turkiye
| | - Fikrettin ŞAHİN
- Department of Genetics and Bioengineering, Faculty of Engineering, Yeditepe University, İstanbul,
Turkiye
| | - Dilek TELCİ
- Department of Genetics and Bioengineering, Faculty of Engineering, Yeditepe University, İstanbul,
Turkiye
| |
Collapse
|
2
|
Kocak P, Oz UC, Bolat ZB, Ozkose UU, Gulyuz S, Tasdelen MA, Yilmaz O, Bozkir A, Sahin F, Telci D. The Utilization of Poly(2-ethyl-2-oxazoline)-b-Poly(ε-caprolactone) Ellipsoidal Particles for Intracellular BIKDDA Delivery to Prostate Cancer. Macromol Biosci 2020; 21:e2000287. [PMID: 33191572 DOI: 10.1002/mabi.202000287] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2020] [Revised: 10/08/2020] [Indexed: 11/10/2022]
Abstract
Prostate cancer is the most common cancer, which is about 15-20% among male cancers worldwide. As most common strategies such as radiotherapy, chemotherapy, or surgery alone can be unsuccessful in the treatment of prostate cancer, this study aims to develop a new approach to deliver newly generated proapoptotic gene, BIKDDA, to androgen independent prostate cancer cells, 22RV1, using new generation nanocarriers called ellipsoids. As far as it is known, this is the first study that assesses the ability of proapoptotic gene BIKDDA to induce apoptosis in prostate cancer cell. BIKDDA encapsulating PEtOx-b-PCL-based ellipsoids are fabricated by solvent-switch method, and their morphology, size, and BIKDDA content are characterized. Gene delivery efficiency of BIKDDA loaded PEtOx-b-PCL ellipsoids is demonstrated by analysis of BIK mRNA expression with real-time PCR. The apoptotic effect of PEtOx-b-PCL ellipsoids loaded with BIKDDA (EPs-BIKDDA) on 22RV1 is shown by Annexin V staining. The obtained results demonstrate that the treatment of 22RV1 cells with EPs-BIKDDA can significantly increase BIK mRNA levels by 4.5-fold leading to cell death. This study not only represents BIKDDA as a potential therapeutic strategy in prostate cancer but also the capacity of ellipsoids as promising in vivo gene delivery vehicles.
Collapse
Affiliation(s)
- Polen Kocak
- Department of Genetics and Bioengineering, Faculty of Engineering and Architecture, Yeditepe University, 26 Agustos Campus, Istanbul, 34755, Turkey
| | - Umut Can Oz
- Department of Pharmaceutical Technology, Faculty of Pharmacy, Ankara University, Yenimahalle, Ankara, 06560, Turkey
| | - Zeynep Busra Bolat
- Department of Genetics and Bioengineering, Faculty of Engineering and Architecture, Yeditepe University, 26 Agustos Campus, Istanbul, 34755, Turkey.,Department of Molecular Biology and Genetics, Faculty of Engineering and Natural Sciences, Istanbul Sabahattin Zaim University, Kucukcekmece, Istanbul, 34303, Turkey
| | - Umut Ugur Ozkose
- U. U. Ozkose, S. Gulyuz, Dr. O. Yilmaz, Materials Institute, Marmara Research Center, TUBITAK, Gebze, Kocaeli, 41470, Turkey.,Department of Chemistry, Faculty of Science and Letters, Istanbul Technical University, Maslak, Istanbul, 34469, Turkey.,Department of Chemistry, Faculty of Science and Letters, Piri Reis University, Tuzla, Istanbul, 34940, Turkey
| | - Sevgi Gulyuz
- U. U. Ozkose, S. Gulyuz, Dr. O. Yilmaz, Materials Institute, Marmara Research Center, TUBITAK, Gebze, Kocaeli, 41470, Turkey.,Department of Chemistry, Faculty of Science and Letters, Istanbul Technical University, Maslak, Istanbul, 34469, Turkey
| | - Mehmet Atilla Tasdelen
- Department of Polymer Engineering, Faculty of Engineering, Yalova University, Yalova, 77200, Turkey
| | - Ozgur Yilmaz
- U. U. Ozkose, S. Gulyuz, Dr. O. Yilmaz, Materials Institute, Marmara Research Center, TUBITAK, Gebze, Kocaeli, 41470, Turkey
| | - Asuman Bozkir
- Department of Pharmaceutical Technology, Faculty of Pharmacy, Ankara University, Yenimahalle, Ankara, 06560, Turkey
| | - Fikrettin Sahin
- Department of Genetics and Bioengineering, Faculty of Engineering and Architecture, Yeditepe University, 26 Agustos Campus, Istanbul, 34755, Turkey
| | - Dilek Telci
- Department of Genetics and Bioengineering, Faculty of Engineering and Architecture, Yeditepe University, 26 Agustos Campus, Istanbul, 34755, Turkey
| |
Collapse
|
3
|
Oz UC, Bolat ZB, Poma A, Guan L, Telci D, Sahin F, Battaglia G, Bozkır A. Prostate cancer cell-specific BikDDA delivery by targeted polymersomes. APPLIED NANOSCIENCE 2020. [DOI: 10.1007/s13204-020-01287-0] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
|
4
|
The pro-apoptotic paradox: the BH3-only protein Bcl-2 interacting killer (Bik) is prognostic for unfavorable outcomes in breast cancer. Oncotarget 2017; 7:33272-85. [PMID: 27120789 PMCID: PMC5078093 DOI: 10.18632/oncotarget.8924] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2016] [Accepted: 04/10/2016] [Indexed: 01/24/2023] Open
Abstract
Breast cancer is the leading cause of cancer-associated deaths in women worldwide. Clinical biomarkers give information on disease progression and identify relevant biological pathways. A confounding factor that uncouples markers from disease outcome is the ability of tumor cells to mutate and evade clinical intervention. Therefore, we focussed on apoptotic genes that modulate tumor regression. Using gene and tissue microarray analyses, we identified an association of Bcl-2 interacting killer (Bik) with poor breast cancer prognosis. Bik prognostic ability was independent of Estrogen Receptor/Progesterone Receptor and Her2 status. Additionally, Bik was independent of anti-apoptotic Bcl-2, Bcl-xL, Mcl-1 and Bcl-w suggesting a complex mechanism of tumor promotion identified by Bik high tumors. Bik also stimulates autophagy, which can contribute to enhanced tumor fitness. We found a significant association between the autophagy marker ATG5 and Bik. Combined high expression level of ATG5 and Bik was a stronger predictor of outcome than either alone. Thus, our study identifies Bik as a novel, independent prognostic biomarker for poor outcomes in breast cancer and suggests that Bik-mediated autophagy contributes to disease recurrence.
Collapse
|
5
|
Dai HY, Chen HY, Lai WC, Hung MC, Li LY. Targeted expression of BikDD combined with metronomic doxorubicin induces synergistic antitumor effect through Bax activation in hepatocellular carcinoma. Oncotarget 2016; 6:23807-19. [PMID: 26247632 PMCID: PMC4695153 DOI: 10.18632/oncotarget.4278] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2015] [Accepted: 06/05/2015] [Indexed: 12/22/2022] Open
Abstract
Conventional chemotherapy is commonly used to treat advanced non-resectable hepatocellular carcinoma (HCC) but this treatment modality has not demonstrated convincing survival benefit in HCC patients. Our previous studies indicated that targeted expression of therapeutic BikDD driven by a liver cancer-specific α-fetoprotein promoter/enhancer (eAFP) in the VISA backbone (eAFP-VISA-BikDD) significantly and specifically kills HCC cells in multiple orthotopic animal models. To enhance its therapeutic efficacy, we combined eAFP-VISA-BikDD with chemotherapeutic agents and found that eAFP-VISA-BikDD plus doxorubicin (Dox) or 5-fluorouracil (5-FU) demonstrated synergistic cytotoxicity in HCC cells. Specifically, the combination of eAFP-VISA-BikDD plus Dox markedly induced apoptosis via increased Bax mitochondrial translocation and cytoplasmic cytochrome c release. Compared with either agent alone, a low dose of Dox combined with eAFP-VISA-BikDD induced better antitumor effect and prolonged longer survival of mice in two orthotopic liver cancer xenograft models. Our findings provide strong preclinical support for evaluating the combined therapy of eAFP-VISA-BikDD and Dox in a clinical setting as a treatment option for HCC.
Collapse
Affiliation(s)
- Huei-Yue Dai
- Center for Molecular Medicine, China Medical University Hospital, Taichung, Taiwan
| | - Hui-Yu Chen
- Graduate Institute of Cancer Biology, China Medical University, Taichung, Taiwan
| | - Wei-Chen Lai
- Graduate Institute of Cancer Biology, China Medical University, Taichung, Taiwan
| | - Mien-Chie Hung
- Center for Molecular Medicine, China Medical University Hospital, Taichung, Taiwan.,Graduate Institute of Cancer Biology, China Medical University, Taichung, Taiwan.,Department of Biotechnology, Asia University, Taichung, Taiwan.,Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Long-Yuan Li
- Center for Molecular Medicine, China Medical University Hospital, Taichung, Taiwan.,Graduate Institute of Cancer Biology, China Medical University, Taichung, Taiwan.,Department of Biotechnology, Asia University, Taichung, Taiwan
| |
Collapse
|
6
|
Sun Y, Ponz-Sarvise M, Chang SS, Chang WC, Chen CH, Hsu JL, Hung MC. Proteasome inhibition enhances the killing effect of BikDD gene therapy. Am J Transl Res 2015; 7:319-327. [PMID: 25901200 PMCID: PMC4399095] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/02/2015] [Accepted: 01/10/2015] [Indexed: 06/04/2023]
Abstract
BikDD, a phosphorylation-mimic mutant of pro-apoptotic protein Bik, elicits strong apoptosis in cancer cells when introduced via an expression platform termed VP16-GAL4-WPRE integrated systemic amplifier (VISA) under the control of a cancer-specific promoter both in vitro and in vivo. C-VISA-BikDD expression plasmid encapsulated in liposomes is currently in the process to initiate a phase I clinical trial for pancreatic cancer. In this study, we report a potential combination approach of BikDD with proteasome inhibitors on the basis of our findings that exogenously expressed BikDD protein undergoes proteasome-mediated degradation via both ubiquitin-dependent and -independent pathways. Inhibition of proteasome increases the protein stability of BikDD, enhancing the apoptotic effect of BikDD. Hence, high proteasome activity may be a mechanism by which intrinsic and acquired resistance occurs in BikDD gene therapy, and a combination therapy with current clinically approved proteasome inhibitor may overcome resistance.
Collapse
Affiliation(s)
- Ye Sun
- Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer CenterHouston, Texas 77030, USA
- Graduate School of Biomedical Sciences, The University of Texas Houston Health Science CenterHouston, Texas 77030, USA
- Present Address: Department of Biological Sciences, Florida Atlantic UniversityBoca Raton, FL 33431, USA
| | - Mariano Ponz-Sarvise
- Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer CenterHouston, Texas 77030, USA
- Present Address: Cold Spring Harbor LaboratoryCold Spring Harbor, NY 11724, USA
| | - Shih-Shin Chang
- Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer CenterHouston, Texas 77030, USA
- Graduate School of Biomedical Sciences, The University of Texas Houston Health Science CenterHouston, Texas 77030, USA
| | - Wei-Chao Chang
- Center for Molecular Medicine and Graduate Institute of Cancer Biology, China Medical UniversityTaichung 404, Taiwan
| | - Chung-Hsuan Chen
- Genomics Research Center, Academia SinicaNankang, Taipei 105, Taiwan
| | - Jennifer L Hsu
- Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer CenterHouston, Texas 77030, USA
- Center for Molecular Medicine and Graduate Institute of Cancer Biology, China Medical UniversityTaichung 404, Taiwan
- Department of Biotechnology, Asia UniversityTaichung 404, Taiwan
| | - Mien-Chie Hung
- Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer CenterHouston, Texas 77030, USA
- Graduate School of Biomedical Sciences, The University of Texas Houston Health Science CenterHouston, Texas 77030, USA
- Center for Molecular Medicine and Graduate Institute of Cancer Biology, China Medical UniversityTaichung 404, Taiwan
- Department of Biotechnology, Asia UniversityTaichung 404, Taiwan
| |
Collapse
|